MedTrace Logo

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NCT04135833 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-04-22

No results posted yet for this study

Summary

This is a phase I study to assess the effect of itraconazole and rifampicin on the pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.

Conditions

Interventions

DRUG

BPI-7711

BPI-7711 60 mg

DRUG

BPI-7711

BPI-7711 180 mg

DRUG

Itraconazole

Itraconazole 200 mg

DRUG

Rifampicin

Rifampicin 600 mg

Sponsors & Collaborators

  • Beta Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jingying Jia · Shanghai Xuhui Central Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-12
Primary Completion
2020-07-22
Completion
2020-07-22

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04135833 on ClinicalTrials.gov